Stock 6600 SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Delayed Hong Kong S.E.
Other stock markets
 02:58:51 2024-05-23 am EDT 		5-day change 1st Jan Change
18.34 HKD +0.11% Intraday chart for SciClone Pharmaceuticals (Holdings) Limited +0.44% +31.61%
May. 16 Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
Apr. 18 Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Its low valuation, with P/E ratio at 10.35 and 9.64 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED Stock SciClone Pharmaceuticals (Holdings) Limited
+31.61% 1.42B -
CSL LIMITED Stock CSL Limited
-1.62% 89.22B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.24% 40.49B
A-
BIOGEN INC. Stock Biogen Inc.
-12.97% 32.79B
B-
UCB Stock UCB
+62.80% 26.23B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.71% 14.52B
C
INCYTE CORPORATION Stock Incyte Corporation
-7.31% 13.09B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.64% 11.5B
D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.60% 11.6B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.27% 8.82B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6600 Stock
  4. Ratings SciClone Pharmaceuticals (Holdings) Limited